Ai Mediq announces it’s participation in largest professional event in MENA region – Arab Health 2020. The event will...Read More
Ai Mediq is happy to introduce the world’s first Medical Device for providing
individualised, biofeedback-controlled Intermittent Hypoxia-Hyperoxia Therapy.
ReOxy is the only medical IHHT device in the world which is regulatory
approved (TUV Rheinland) and CE-marked for professional healthcare use.
ReOxy offers innovative solution that improves quality of life of patients and enhances fitness of healthy individuals. ReOxy safely increases physical capacity without doing exercise and improves cardiovascular risk factors profile in individuals including seniors, patients with severely decreased functional capabilities and the disabled. ReOxy treatment has minimal limitations associated with exercise.
ReOxy is the first medical IHHT device for professional healthcare market which is available worldwide. The personalised approach allows using the IHHT method in patients of various age, sex and nosology groups, including seniors with dementia and frailty, and other patients with apparent physical limitations. ReOxy represents the clinically effective solution for these patients.
ReOxy is easy-to-use: built-in intelligent software automatically calculates the procedure parameters based upon the results of a pre-treatment hypoxic test, and then controls and adjusts them in real-time during the whole treatment session to ensure high effectiveness and safety of the treatment. Competent technical and scientific support is available 24/7 by phone, email and popular instant messengers.
Strategic location of our distribution center enables shipment of Ai Mediq products to any part of the world within 48 hours. Competent technical and scientific support is available 24/7 by phone, email and popular instant messengers. Flexible terms for all distributor types. On- and off-site training options for distributor personnel. Comprehensive marketing materials.
Ai Mediq is a Luxembourg-based ground-breaking medical technology company
that develops novel non-invasive therapeutic solutions leveraging
positive treatment effects of high altitude (hypoxic) exposure, medical
devices for Intermittent Hypoxic Treatment, and medical software
algorithms for its personalisation.
Bitmos Gmbh is a company that focuses on design and distribution of sophisticated medical appliances and their on-site expert production. Bitmos designs and manufactures medical devices for patient monitoring, pulse oximetry and respiratory care. Its interdisciplinary teams are expert in developing innovative medical engineering solutions. Bitmos has been fully certified to EN ISO 13485 since 2003, while simultaneously implementing pure digital quality management system.
Besides full-service solutions for development of medical products (incl. industrial design, technical documentation and regulatory affairs), Bitmos team offers product optimisations, feasibility studies and detailed solutions. The core expertise at Bitmos lies in the development of medical electronics and software. All Bitmos products comply with the highest quality standards, and are continuously optimised with respect to ease-of-use and additional useful features. They have a clearly defined usage concept, innovative details, modern design, and high economic efficiency taking into account environmental concerns.
The Сompany is supported by a long-standing Scientific Advisory Board which includes leading EU cardiologists, hypoxia research/altitude medicine specialists, biostatisticians, and healthcare organisation experts.
Ai Mediq has a strong consortium in the field of clinically oriented medical research, including leading EU research organisations, universities and clinics, such as:
- Luxembourg Institute of Health, LU
- Department of Sport Science, University of Innsbruck, AUT
- Eurac Research Bolzano, AUT
- Charite Universitatsmedizin Center for Stroke, DE
- Hermann Buhl Institute, DE
- Department of Cardiology, IRCCS San Raffaele Pisana, Rome, IT
- Istituti Clinici Scientifici Maugeri, IRCCS, Institute of Pavia, IT
- Robertson Centre for Biostatistics & Clinical Trials, Glasgow, UK